This slide show highlights 2016 FDA approvals of cancer treatments, which to date include therapies for RCC, neuroendocrine tumors, Hodgkin lymphoma, CLL, sarcoma, bladder cancer, lung cancer, and breast cancer.
Data Highlight Pervasive Racial/Ethnic Disparities in Health Care
Findings from a health disparities report may support new policies designed to narrow persistent racial and ethnic disparities in health outcomes.
Applying Novel Radiotherapy Technology for Brain Tumors and Other Cancers
Timothy Chen, MD, highlights how technologies such as ZAP-X and proton therapy may improve outcomes for patients with cancer.
Pembrolizumab Combo Yields Significant OS in HER2+ Gastric/GEJ Cancer
The primary end point of overall survival was met in the KEYNOTE-811 trial assessing pembrolizumab in HER2-positive gastrointestinal cancer.
Moving The Needle in Lung Cancer Management With Robotic-Assisted Surgery
Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.
Venetoclax Elicits Enduring Responses in R/R Chronic Lymphocytic Leukemia
Phase 3b data support venetoclax as a treatment option in CLL for patients with or without B-cell receptor–associated kinase inhibitor treatment.
USPSTF Recommends Breast Cancer Screening Starting at Age 40
Biennial screening mammography is recommended for those who are 40 to 74 years old rather than individualizing screening decisions in this age group.